|Articles|July 4, 2020
- June 2020
- Volume 3
- Issue 2
Hereditary Angioedema: Management Updates for the Specialty Pharmacist
This continuing education activity is supported by an educational grant from Takeda.
Advertisement
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM TAKEDA.
FACULTY
Melanie B. Radi, PharmD, CSP
Manager, Clinical Programs Specialty Clinical Services
AllianceRx Walgreens Prime
Pittsburgh, Pennsylvania
At the completion of this activity, the participant will be able to:
- Characterize the diagnosis and background of hereditary angioedema (HAE) and the significance of early intervention
- Examine the clinical data of FDA-approved agents and emerging therapies for acute treatment and prophylaxis of HAE
- Explore the need for individualized treatment and the role of the specialty pharmacist in patient education for effective HAE management
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: May 15, 2020
EXPIRATION DATE: May 15, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
about 6 years ago
CIDP Care: A Patient and Clinical Experts Weigh Inabout 6 years ago
JAK Inhibitors Are Important Tools for Patients With Myelofibrosisabout 6 years ago
The Multidisciplinary Team Improves Cystic Fibrosis OutcomesAdvertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare's New GLP-1 Bridge Program: What Pharmacists Need to Know Before Dispensing
2
GLP-1 RAs Linked to Lower Mortality, Amputation Risk in Patients With PAD and Type 2 Diabetes
3
Pharmacists Can Help Patients Navigate GLP-1 Access, Affordability, and Long-Term Use
4
Clots, Catheters, and Clinical Pearls: Pulmonary Embolism Updates for Practicing Pharmacists
5